RanjitKSMD Profile Banner
Ranjit Kumar Sahoo Profile
Ranjit Kumar Sahoo

@RanjitKSMD

Followers
2K
Following
3K
Media
43
Statuses
826

Medical Oncologist, AIIMS, New Delhi, India. Opinions are my own.

New Delhi
Joined January 2020
Don't wanna be here? Send us removal request.
@RanjitKSMD
Ranjit Kumar Sahoo
9 days
PD-1 inhibitors give a strong short-term effector burst… …but may reduce the long-term reservoir of stem-like T cells.
@DaisukeKotani
Daisuke Kotani, MD, Ph.D 小谷 大輔
10 days
The Role of PD-1 in Maintaining Stem-like CD8+ T Cells @Nature ✅PD-1 doesn’t just “brake” — it fine-tunes TCR signaling to prevent exhaustion of precious stem-like CD8+ T cells ✅Blocking PD-1 can depletes these stem-like progenitors 👉PD-1 might be less an off-switch and more
0
0
1
@RanjitKSMD
Ranjit Kumar Sahoo
17 days
Absolutely.
@DaisukeKotani
Daisuke Kotani, MD, Ph.D 小谷 大輔
17 days
"Badscopal Effect" of Radiotherapy ✅Radiotherapy-induced amphiregulin can promote outgrowth of previously dormant distant lesions. 👉Emergence of distant metastases does not often appear immediately after radiotherapy in clinical practice. "Badscopal effect" could occur only in
0
0
0
@RanjitKSMD
Ranjit Kumar Sahoo
21 days
Good job Vineeth.
@Vineeth06760017
Vineeth Kumar
22 days
Vineeth Kumar: Phase II High-Dose Ifosfamide in Metastatic/ Unresectable Synovial Sarcoma https://t.co/z27p1s1KBE Thank you @oncodaily for sharing!!
1
0
2
@RanjitKSMD
Ranjit Kumar Sahoo
1 month
#CWC25 IndvsAus
0
0
2
@RanjitKSMD
Ranjit Kumar Sahoo
2 months
ATG Repurposed!
@TheLancet
The Lancet
2 months
Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial
0
0
5
@RanjitKSMD
Ranjit Kumar Sahoo
3 months
Just wonderful!
@DrJNaidoo
Jarushka Naidoo
3 months
Best slides of #WCLC25? @charocampelo gave an incredible talk on Work-Life harmony & models of leadership, the giraffe leadership analogy🦒 - sees problems with clarity & calm - just by moving, others follow - great relationship with its environment @IASLC @Women4Oncology
0
1
8
@RanjitKSMD
Ranjit Kumar Sahoo
3 months
Awesome. ADC plus BiTE (?ADiTE) strategy in oncology will take a centre place🤞. DLBCL showed the way.
@AuclairDan
Daniel Auclair
3 months
Dr. Juan Pablo Alderuccio presenting at #SOHO25 the Ph. 1b data of the LOTIS-7 trial (lonca + glofi in R/R DLBCL): - 93.3% ORR and a CR rate of 86.7% - No grade 5 TAEs and median time to first response (CR or PR) was 42 days - Rates of CRS and ICANS were low #lymsm
0
0
2
@drshrinidhi2020
Shrinidhi Nathany
3 months
HemaNextReads #2 CHIP isn’t static—it’s dynamic. A 16-yr Blood study in ~7,000 women: •25% clones vanished •25% shrank •50% expanded Fastest growers: SF3B1, JAK2 Germline + telomeres modulate growth Clone growth rate = major predictor of leukemia & mortality ➡️ Risk = speed
Tweet card summary image
ashpublications.org
Key PointsGerm line genetic variants, telomere biology, and interleukin-6 signaling influence CH expansion.Dynamics of CH are associated with incident cyto
0
2
5
@DrRishabhOnco
Dr Rishabh Jain
3 months
🎲 Cancer is a game of chance - but we don’t let it win. Enter the Goldie–Coldman hypothesis: why we hit tumors early & hard with combo chemo 💊💊 📊 The math of resistance • Each cell division = 🎲 roll for mutation • Bigger tumor = 🎯 higher odds a resistant clone already
2
18
50
@DrRishabhOnco
Dr Rishabh Jain
3 months
⚠️ Dasatinib: powerful in theory, problematic in practice. 🧬 Mechanism of toxicity Dasatinib is a multi-kinase inhibitor -not only BCR-ABL, but also Src family, PDGFR, c-KIT. 👉 This broad inhibition drives efficacy and unpredictable toxicities: 🌊 Pleural effusions →
1
2
4
@RanjitKSMD
Ranjit Kumar Sahoo
3 months
Good job
@DrRishabhOnco
Dr Rishabh Jain
3 months
🧬 CD38: Not just a plasma cell marker 🔬 Biology 🧫 HSCs: CD34⁺CD38⁻ (primitive) 🌱 Early precursors: CD34⁺CD38⁺ (commitment → CD38 turns on) 😴 Resting lymphocytes: CD38 low/off 🔆 Plasma cells: CD38+ bright with CD138 🧨 Malignancies: AML/APL blasts, CLL, myeloma
0
0
2
@RanjitKSMD
Ranjit Kumar Sahoo
4 months
Just wonderful. Attaching herewith a recent study which combines Thalidomide, Methotrexate and Low-dose prednisone in TGLL. Responses never documented before. Potentially practice changing.
Tweet card summary image
nature.com
Signal Transduction and Targeted Therapy - Thalidomide-based regimen shows promising efficacy in large granular lymphocytic leukemia: a multicenter phase II study
@DrRishabhOnco
Dr Rishabh Jain
4 months
🔥 LGL leukemia: tiny clone, outsized havoc 🧭 What it is? Clonal expansion of cytotoxic T or NK LGLs; often indolent but drives cytopenias + autoimmunity. 🔎 Diagnose smart: Persistent LGLs (≥6 mo) ➕ flow (T-LGL: CD3⁺CD8⁺CD57⁺; NK-LGL: CD3⁻CD16/56⁺) ➕ TCR
0
2
9
@RanjitKSMD
Ranjit Kumar Sahoo
4 months
Find some interesting studies from our institute. https://t.co/ZkwoZPvcKh https://t.co/s7Xtz8mEsU
Tweet card summary image
pmc.ncbi.nlm.nih.gov
Acute Myeloid Leukemia (AML) as per World Health Organization (WHO 2008) classification is on the basis of the antigenic characterization, enzymes restriction in the neoplastic myeloid cells and the...
@DrRishabhOnco
Dr Rishabh Jain
4 months
🧬 MPO in AML: which test wins? 📊 Flow cytometry (cMPO) • 🥇 Frontline for lineage assignment • EGIL cut-off = 10% blasts • Newer data: ~28% cut-off → ↑ Sens ~97% | Spec ~96% 🧫 Immunohistochemistry(MPO on core) • Best for dry taps / hemodilution • Often more sensitive
0
0
4
@RanjitKSMD
Ranjit Kumar Sahoo
4 months
Dr. Sneh Bhargava — from Partition refugee to AIIMS’s first woman Director, she revolutionised Indian radiology and led with purpose, not prestige .
@thebetterindia
The Better India
4 months
“CT scanners for the masses? India can’t afford it,” they said. But she didn’t stop. At just 17, Sneh Bhargava fled Partition with nothing but fierce determination to study and heal. From being the only woman in her radiology department to becoming AIIMS’ first woman
1
0
12
@RanjitKSMD
Ranjit Kumar Sahoo
4 months
A very nicely written obituary. Had the opportunity to interact with him and his daughter (Peggy Lu) in 2019 in Beijing while pursuing the ASH-VTP program. A mentor par excellence.
Tweet card summary image
nature.com
Bone Marrow Transplantation - Professor LU Daopei: Chinese Transplant Pioneer, 30 October, 1931–2 April, 2025
0
0
4
@Deba_91
Debabrata Mohapatra
4 months
https://t.co/Yq7b2ICMxM Glad to share our experience on umbilical cord blood transplant at @aiims_newdelhi, the 1st such data from India & South-Asia.. From registry search to survival... Thankful to my teachers @drsameerbakhshi, @RanjitKSMD, @DeepamPushpam, & every team member.
Tweet card summary image
link.springer.com
Indian Pediatrics - There is dearth of clinical data from India regarding outcomes of umbilical cord blood transplant (UCBT). This study aimed to analyze the long-term outcomes in children who...
0
1
5
@RanjitKSMD
Ranjit Kumar Sahoo
5 months
First do no harm. Sorry for the typo
0
1
4
@RanjitKSMD
Ranjit Kumar Sahoo
5 months
Inflammation and the Hematologic Spectrum: CHIP, CCUS, MDS, and CMML — Another example of “The Inflammation-to-Cancer Continuum”
@ellaette
Michelle Robinette
5 months
I always consider hematologic malignancy in a suspected vasculitis diagnosis- ideally with @CarrawayHetty @ACR_Journals
0
0
4
@RanjitKSMD
Ranjit Kumar Sahoo
5 months
Plea for humility in medical practice. In short: First do harm..
@DrOribaDan
Dr. Oriba Dan Langoya
5 months
Take time to read this book diligently as a medical student and begin at the very beginning. Start with "Hutchison’s Prayer." Recite & paste it in your brain.
2
1
6